ArticleBMC surgery2025
Clinical application of preoperative volumetric measurement for interventional precise embolization in the treatment of hypersplenism caused by liver cirrhosis.
Article in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Splenectomy to Partial Splenic Embolization, Which is Better for Hereditary Spherocytosis?Journal of blood medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveVolume measurement software is not routinely utilized in clinical practice before splenic artery embolization. To explore the function of such software measurement in this context, we conducted a retrospective study.
methodsWe divided patients into two groups: 38 patients in Group A underwent three-dimensional reconstruction using Revolution CT, and 37 patients in Group B underwent imaging with normal CT technology. We compared the changes in liver function test results and haematological parameters between these two groups.
resultsA total of 75 patients who underwent splenic artery embolization from January 2018 to January 2023 were included. The preoperative baseline data were not significantly different (all P values > 0.05). Both groups showed improvements in liver function and hypersplenism-related parameters. Within 2 weeks after surgery, Group A had significantly greater WBC (5.54 ± 1.92 × 10^9/L) and PLT (65.80 ± 20.12 × 10^9/L) counts than Group B (WBC: 4.14 ± 1.96 × 10^9/L; PLT: 52.70 ± 14.78 × 10^9/L; P < 0.05), indicating better control of hypersplenism. At 2 months postintervention, Group A demonstrated more favourable improvements in postintervention splenic volume (reduced from 1045 ± 122.9 cm³ to 489.5 ± 84.93 cm³), portal vein diameter (from 1.51 ± 0.19 cm to 1.28 ± 0.13 cm), and portal vein flow velocity (increased from 17.70 ± 5.25 cm/s to 23.56 ± 6.40 cm/s) than Group B. Moreover, a 53.2% splenic volume reduction was noted in Group A, which was significantly greater than the 31.4% reduction in Group B. Additionally, Group A had fewer adverse reactions, with lower liver/gastrointestinal toxicity (χ²=4.242, P = 0.039) and fever severity (χ²= 4.805, P = 0.028).
conclusionsThis study suggests that using Revolution CT prior to splenic artery embolization provides an effective method for managing hypersplenism, enhancing liver function, and reducing the risk of complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.